Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 8/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.40 |
| ▸ | FLT4 | P35916 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165430 | 1.00 | F11 (0.41) | F11FLT1FLT4KDRTP53 | |
| SCHEMBL10165434 | 0.92 | TP53 (0.45) | F11FLT1FLT4KDRTP53 | |
| SCHEMBL10165454 | 0.86 | KMT2A (0.43) | TP53MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4876125 | 0.86 | GPR27 (0.40) | FLT1FLT4KDRTP53MAPK1 | |
| SCHEMBL10165439 | 0.86 | GPR27 (0.40) | FLT1FLT4KDRTP53MAPK1 | |
| SCHEMBL4876121 | 0.86 | GPR27 (0.40) | FLT1FLT4KDRTP53MAPK1 | |
| SCHEMBL1102057 | 0.81 | MEN1 (0.60) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL10165494 | 0.80 | TRAF6 (0.46) | FLT1FLT4KDRTP53MAPK1 | |
| SCHEMBL10165491 | 0.77 | KMT2A (0.41) | TP53MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10165448 | 0.77 | KMT2A (0.41) | TP53MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | F11 3142/4885FLT1 4785/4885FLT4 4714/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | F11 3142/4885FLT1 4785/4885FLT4 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.